Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 19/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925068 | 1.00 | KCNJ1 (0.73) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL17925028 | 0.95 | KCNJ1 (0.76) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL17925027 | 0.95 | KCNJ1 (0.76) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL17925135 | 0.95 | KCNJ1 (0.70) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL17925133 | 0.95 | KCNJ1 (0.70) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2909534 | 0.88 | KCNJ1 (0.74) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2894656 | 0.88 | KCNJ1 (0.74) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL18204149 | 0.87 | KCNJ1 (0.59) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16862655 | 0.87 | KCNJ1 (0.59) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL14933602 | 0.85 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027625-B1 | SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170275298-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | WUXI APPTEC (SHANGHAI) CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-9751881-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 22/4885ACHE 4852/4885 |
| US-20170275298-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 22/4885ACHE 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.